BlossomHill Therapeutics Q3 2026 Results: Net Loss of $24M, Loss Widens
BlossomHill Therapeutics is a clinical-stage biopharmaceutical company with two product candidates, BH-30643 and BH-30236, in early clinical development and one preclinical candidate, BH-501284. The company has incurred substantial losses since inception and anticipates continued losses as it advances its precision medicine programs for genetically defined cancers.
- Key figure
- Net loss $24M